Creatinine Clearance Is Not Equal to Glomerular Filtration Rate and Cockcroft-Gault Equation Is Not Equal to CKD-EPI Collaboration Equation

American Journal of Medicine

Volumn 129, Issue 12, 2016, Pages 1259-1263

  Fernandez Prado, Raul ^a,b   Castillo Rodriguez, Esmeralda ^a,b   Velez Arribas, Fernando Javier ^a   Gracia Iguacel, Carolina ^a,b,c   Ortiz, Alberto ^a,b,c  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN JIMÉNEZ DÍAZ   (Spain)

^b REDINREN   (Spain)

^c Section of Nephrology   (Spain)

Author keywords

Atrial fibrillation; Chronic kidney disease; Creatinine clearance; Glomerular filtration rate; Oral anticoagulation

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; CREATININE; DABIGATRAN; RIVAROXABAN; WARFARIN;

ANTICOAGULANT THERAPY; ATRIAL FIBRILLATION; CHRONIC KIDNEY DISEASE EPIDEMIOLOGY COLLABORATION EQUATION; CLINICAL TRIAL (TOPIC); COCKCROFT GAULT EQUATION; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; ESTIMATED GLOMERULAR FILTRATION RATE; GLOMERULUS FILTRATION RATE; HUMAN; MATHEMATICAL PARAMETERS; PRIORITY JOURNAL; REVIEW; THROMBOEMBOLISM; BLOOD; CHRONIC KIDNEY FAILURE; CLINICAL PRACTICE; COMPLICATION; DOSE RESPONSE; DRUG EFFECTS; KIDNEY FUNCTION TEST; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PROCEDURES; STANDARDS;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FUNCTION TESTS; PRACTICE PATTERNS, PHYSICIANS'; RENAL INSUFFICIENCY, CHRONIC;

EID: 84996590326     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2016.08.019     Document Type: Review

References (16)

1. 1 Stevens, L.A., Li, S., Wang, C., et al. Prevalence of CKD and comorbid illness in elderly patients in the United States: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 55:3 suppl 2 (2010), S23–S33.
2. 2 Ruff, C.T., Ansell, J.E., Becker, R.C., et al. North American Thrombosis Forum, AF Action Initiative Consensus Document. Am J Med 129:5 suppl (2016), S1–S29.
3. 3 Barra, M.E., Fanikos, J., Connors, J.M., Sylvester, K.W., Piazza, G., Goldhaber, S.Z., Evaluation of dose-reduced direct oral anticoagulant therapy. Am J Med, 2016, 10.1016/j.amjmed.2016.05.041 [Epub ahead of print].
4. 4 Cockcroft, D.W., Gault, M.H., Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976), 31–41.
5. 5 Levey, A.S., Bosch, J.P., Lewis, J.B., Greene, T., Rogers, N., Roth, D., A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:6 (1999), 461–470.
6. 6 Levey, A.S., Stevens, L.A., Schmid, C.H., et al., CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 150:9 (2009), 604–612.
7. 7 Highlights of prescribing information. PRADAXA® (dabigatran etexilate mesylate) capsules for oral use. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022512s017lbl.pdf. Accessed July 30, 2016.
8. 8 Highlights of prescribing information. SAVAYSA (edoxaban) tablets for oral use. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf. Accessed July 30, 2016.
9. 9 Highlights of prescribing information. XARELTO (rivaroxaban) tablets, for oral use. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022406s004lbl.pdf; http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202155s000lbl.pdf. Accessed July 30, 2016.
10. 10 Hohnloser, S.H., Hijazi, Z., Thomas, L., et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 33 (2012), 2821–2830.
11. 11 Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 3 (2013), 1–150.
12. 12 KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for the Evaluation and Management of CKD. Am J Kidney Dis 63 (2014), 713–735.
13. 13 Maccallum, P.K., Mathur, R., Hull, S.A., et al. Patient safety and estimation of renal function in patients prescribed new oral anticoagulants for stroke prevention in atrial fibrillation: a cross-sectional study. BMJ Open, 3, 2013, e003343.
14. 14 Manzano-Fernández, S., Andreu-Cayuelas, J.M., Marín, F., et al. Comparison of estimated glomerular filtration rate equations for dosing new oral anticoagulants in patients with atrial fibrillation. Rev Esp Cardiol 68 (2015), 497–504.
15. 15 Parsh, J., Seth, M., Aronow, H., et al. Choice of estimated glomerular filtration rate equation impacts drug-dosing recommendations and risk stratification in patients with chronic kidney disease undergoing percutaneous coronary interventions. J Am Coll Cardiol 65 (2015), 2714–2723.
16. 16 Granger, C.B., Alexander, J.H., McMurray, J.J., et al., ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365 (2011), 981–992.